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Abstract
The somatic, neurocognitive, and psychiatric side effects of biological response modifiers (BRMs) have
been documented in specific patient samples. Although these side effects likely have a predictable impact on
patients quality of life (QOL), no instrument currently measures the cumulative effect of the various
complaints patients’ report. The current study investigated the reliability and validity of the Functional
Assessment of Cancer Treatment-Biological Response Modifier (FACT-BRM) scale for measuring QOL in
a sample of melanoma patients receiving interferon. Measures of distress, depression, and fatigue were also
obtained using standardized, well-validated instruments. Results indicate increased symptom burden,
depression, and fatigue, and decreased quality of life over 4 months of IFN therapy. The FACT-BRM
demonstrated good psychometrics and sensitivity to change, and thus appears to be a good instrument for
measuring QOL in patients receiving BRMs.
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Introduction
Recent increased interest in quality of life (QOL)
for cancer patients has prompted the development
of several measures of health-related quality of
life, including the European organization for Re-
search and Treatment of Cancer Quality of Life
Questionnaire [1], the Functional Living Index-
Cancer [2, 3], the Cancer Rehabilitation Evalua-
tion System [4], the Medical Outcome Survey
Short Form-36 [5, 6], and the Functional Assess-
ment of Cancer Treatment (FACT) [7].
The FACT is composed of general subscales
that measure physical, social/family, emotional,
and functional well-being, with additional specific
questions included to address concerns for the
subpopulation of interest. One measure that has
not yet received a great deal of study is the bio-
logical response modifier (BRM) version of the
FACT (FACT-BRM). This version was designed
to measure changes in quality of life associated
with the use of treatments such as interferons and
interleukins, which have demonstrated effective-
ness in treating various conditions but remain
difficult for patients to tolerate.
BRMs are associated with constitutional and
neuropsychiatric side effects [8–11] which are often
dose dependent [12], making higher-dose therapies
(such as those used to treat melanoma) too difficult
for some to tolerate, thus resulting in discontinu-
ation of therapy [13, 14]. Many of the reports of
side effects associated with BRM administration
have been single case studies [15–18], used retro-
spective or cross-sectional designs [19], or used
lower dosages of BRMs than is usually used to
treat melanoma [20]. None have measured
HRQOL associated with high-dose IFN adminis-
tration in melanoma patients prospectively during
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therapy or evaluated the utility of such a specific
HRQOL instrument over the course of high-dose
BRM treatments.
Having accurate information on the QOL and
toxicities associated with administration of BRMs
is important for consideration of these therapies
for the future. Such information requires mea-
surement with a valid, reliable instrument that is
sensitive to the effects of BRMs. The varied side
effects produced by these treatments suggest the
need for multidimensional measures that can
provide an indication of the impact they may have
on QOL. Currently, little is known about the
ability of the FACT-BRM to identify changes in
HRQOL. Thus, the current study was designed to
examine prospectively the HRQOL of a sample of
melanoma patients receiving high-dose interferon-
a-2b over 4 months, and to evaluate the validity,




This study was part of a larger project examining
distress and QOL in interferon-treated melanoma
patients conducted at the University of Michigan
Comprehensive Cancer Center [21]. Individuals
with melanoma who were planned for treatment
with IFN-a-2b at the University of Michigan’s
Comprehensive Cancer Center between April 1999
and February 2002 were eligible for the study if
they were also over the age of 18, read and
understood English, and were able to give their
own consent. Over this period of time, 21 patients
(12 male, 9 female) with resected malignant mela-
noma agreed to participate. Average age of the
participants was 43.67 (12.67); most were married
(71.4%) and employed (57.1%); approximately
half (47.6%) had a college education or higher.
Therapy involved 1 month of high dose IFN-a-
2b administered daily, followed by 11 months of
three times a week self-administered maintenance
therapy at a lower dose. As part of the larger
study, assessments were conducted at baseline
(before IFN therapy was initiated), post-baseline
after 1 month of high dose infusion (PoHD), and
at months 1, 2, 3, 6, 9, and 12 of maintenance
therapy. Since the majority of side effects associ-
ated with IFN present within the first 3 months of
therapy, data from the baseline, PoHD, and the
first two maintenance assessments were examined
for this study. The University of Michigan IRB
approved the study and all patients provided
written consent.
Procedure
Initial contact and administration of baseline and
PoHD questionnaires occurred in a Cancer Center
examination room. Questionnaires completed
after 1 and 2 months of maintenance therapy were
sent to patients and returned through self-ad-
dressed stamped envelopes. Each questionnaire
package consisted of the Brief Symptom
Inventory, Functional Assessment of Cancer
Therapy-Biological Response Modifiers, Revised
Piper Fatigue Scale, and Beck Depression Inven-
tory. The baseline package also obtained demo-
graphic and illness information. Packages took
20–30 min to complete.
Measures
Brief Symptom Inventory (BSI)
The BSI is the short version of the SCL-90-R. It
contains 53 items measuring emotional distress
and takes 5–10 min to complete [22, 23]. Individ-
ual items are answered on a ‘0’ (not at all dis-
tressed) to ‘4’ (extremely distressed) scale and are
summed into one of nine clinical scales and three
summary scales. Principal among these for the
purpose of the current study are the somatization
(as a measure of somatic complaints or symptom
burden) and depression subscales, as these reflect
the primary symptoms that have been identified as
potentially being affected by interferon therapy.
The BSI is standardized using area T-scores, each
with a range from 0 to 100, mean of 50, and
standard deviation of 10.
Functional Assessment of Cancer Treatment-
Biological Response Modifiers (FACT-BRM)
The FACT-BRM is a 40-item questionnaire de-
signed to assess quality of life [7]. Four general
domains cover physical well-being, social/family
well-being, emotional well-being, and functional
well-being. A fifth, targeted domain, assesses
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specific physical and cognitive/emotional concerns
associated with BRM treatments. Each of the 40
items is scored on a five point Likert-type scale
ranging from 0 (Not at all) to 4 (Very much). Raw
subscale scores range from 0 to 24 (emotional,
additional cognitive), or 0 to 28 (physical, social,
functional, additional physical).
Revised Piper Fatigue Scale (RPFS)
The RPFS is a 22-item questionnaire designed to
measure the presence of and interference from fa-
tigue [24]. It is composed of four subscales:
behavioral, affective, sensory, and cognitive. Each
item is scored on a 0–10 Likert-type scale, with
end-points representing extremes (e.g., 0 ¼ None,
10 ¼ A great deal). Subscale scores and a total
fatigue score are obtained by calculating corre-
sponding arithmetic means.
Beck Depression Inventory (BDI)
The BDI is a 21-item self-report questionnaire
assessing the presence and severity of depressive
symptoms [25]. Total scores range from 0 to 63,
with higher scores indicating greater pathology.
Demographic questionnaire
A face valid demographic questionnaire obtained
information on age, race, education, employment
status, marital status, and number of dependents.
Statistical analyses
Descriptive statistics were computed for scales on
each measure at each measurement occasion.
Subscale correlations were measured using Pear-
son product moment correlation coefficients.
Internal consistency was obtained through the use
of coefficient a on the items within each subscale of
the FACT-BRM. Tests of means were conducted
using single sample t-tests. All p values reported
are two-tailed, and all statistical analyses were
performed using the Statistical Package for Social
Sciences, version 10 (SPSS, Inc, Chicago, IL).
Results
Descriptives
Descriptive data are presented in Table 1. Means
and standard deviations of the FACT-BRM sub-
scales, BSI subscales, BDI, and Piper Fatigue
subscales are given for the four assessment points.
The physical, social/family, emotional, and func-
tional subscales, in addition to the additional
mental and additional physical scales of the
FACT-BRM are provided.
Concurrent validity
In order to address the concurrent validity of the
FACT-BRM, Pearson product moment correla-
tions were conducted between the FACT and the
BDI, PFS, and specific subscales of the BSI at the
post-high dose assessment point. This point was
chosen as it was expected that effects due to high-
dose IFN administration would be greatest after
1 month of high dose therapy, relative to the
Table 1. Descriptive analyses at baseline, post high-dose, 1- and 2-months post high-dose (n = 21)
Baseline Post high-dose 1-Month Post high-dose 2-Month post high-dose
FACT-BRM physical 25.12 (3.80) 19.28 (4.13) 19.46 (4.29) 17.67 (4.60)
FACT-BRM social/family 23.88 (5.43) 24.22 (4.30) 24.31 (2.63) 23.10 (2.96)
FACT-BRM emotional 17.85 (4.51) 19.89 (3.08) 19.08 (5.71) 19.75 (2.67)
FACT-BRM functional 21.02 (5.95) 18.22 (5.79) 18.08 (5.76) 18.17 (5.32)
FACT-BRM additional physical 25.50 (2.28) 17.22 (4.56) 17.64 (4.85) 16.85 (5.00)
FACT-BRM additional mental 20.35 (3.42) 17.67 (4.14) 16.64 (5.26) 16.46 (4.61)
BSI somatization 50.20 (8.32) 59.22 (9.94) 58.15 (9.07) 59.17 (9.52)
BSI depression 50.90 (10.25) 51.83 (11.11) 53.62 (10.67) 54.00 (8.61)
Beck depression inventory 5.00 (4.17) 7.56 (3.85) 9.15 (7.13) 9.08 (4.74)
Piper behavior 0.77 (1.22) 3.39 (2.46) 4.00 (2.27) 3.97 (1.91)
Piper affect 1.57 (2.04) 4.03 (2.28) 4.86 (1.92) 4.82 (2.04)
Piper sensory 1.77 (1.82) 4.57 (1.95) 5.11 (1.71) 5.08 (1.44)
Piper cognitive 1.43 (1.66) 2.99 (2.01) 2.88 (1.93) 2.97 (1.67)
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baseline and maintenance phase assessment points.
Based on the literature, we hypothesized consis-
tent, significant associations would demonstrate
convergent validity between FACT-BRM subscale
scores and scores on measures of somatic com-
plaints, depression, and fatigue, once participants
had received IFN, with discriminant validity being
indicated by the absence of significant correlations
[26]. Separate correlation matrices reflecting
hypothesized convergent and discriminant associ-
ations are presented in Tables 2 and 3.
As expected, FACT-BRM subscales were cor-
related with increased depression and somatic
complaints. All baseline correlations were signifi-
cant at the p < 0.05 level except those between
FACT-BRM Emotional and Piper Fatigue Affec-
tive and Behavioral. Corrected for multiple com-
parisons, nearly half of the correlations in Table 2
continued to be significant at the p < 0.001 level,
demonstrating convergent validity. By compari-
son, only six of the correlations in Table 3 were
significant at this level, demonstrating discriminant
validity. Unexpected results were found when BSI
Anxiety and Obsessive–Compulsive scales corre-
lated significantly with selected FACT subscales.
Sensitivity to change
In order to assess the sensitivity to change of the
FACT-BRM, baseline to PoHD scores on the
FACT were subjected to t-tests. We hypothesized
that any changes in HRQOL associated with IFN
administration would be reflected in FACT-BRM
changes from baseline (pre-administration) to
PoHD (after 1 month of daily high dose admin-
istration). In particular, we expected changes in
PWB, FWB, EWB, additional concerns, and total
scores. As expected, changes on all subscales ex-
cept social/family well-being were significant:
PWB t(16) ¼ 5.91, p < 0.001; S/FWB
Table 2. Concurrent validity: post-high dose convergent correlations (n = 21)
FACT-BRM FACT





BSI somatization )0.693* )0.667** )0.645** )0.771* )0.626** )0.761*
BSI depression )0.416 )0.638** )0.665** )0.525** )0.792* )0.755*
Beck depression inventory )0.720* )0.667** )0.903* )0.784* )0.839* )0.908*
Piper fatigue behavioral )0.747* )0.309 )0.490** )0.638** )0.524** )0.557**
Piper fatigue affective )0.546** )0.298 )0.493** )0.466** )0.531** )0.527**
Piper fatigue sensory )0.810* )0.410 )0.589** )0.694* )0.723* )0.733*
Piper fatigue cognitive )0.577** )0.808* )0.727* )0.580** )0.786* )0.780*
Piper fatigue Total )0.787* )0.539** )0.691* )0.677** )0.762* )0.761*
*p<0.001; **p<0.05.
Table 3. Concurrent validity: discriminant correlations of FACT-BRM subscales at post-high dose (n = 21)
FACT Additional FACT
Physical Emotional Functional Physical Cog/Emot total
BSI anxiety )0.204 )0.724* )0.571** )0.539** )0.756* )0.686**
BSI hostility )0.238 )0.209 )0.187 )0.144 )0.256 )0.268
BSI psychoticism )0.728** )0.295 )0.464 )0.513 )0.608** )0.615**
BSI phobic anxiety )0.371 )0.220 )0.597** )0.489 )0.545 )0.510
BSI obsessive-compulsive )0.791* )0.633** )0.788* )0.707** )0.834* )0.856*
BSI interpersonal sensitivity )0.335 )0.255 )0.435 )0.560** )0.329 )0.434
BSI paranoid ideation )0.174 )0.083 )0.386 )0.029 )0.388 )0.268
*p<0.001; **p<0.05.
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t(16) ¼ )0.09, ns; EWB t(16) ¼ )0.2786,
p < 0.05; FWB t(16) ¼ 2.27, p < 0.05; AC
t(16) ¼ 6.72, p < 0.001; FACT Total t(16) ¼ 4.67,
p < 0.001.
Change scores from Baseline to PoHD were
then created on the Total FACT-BRM and all its
subscales. These were then correlated with change
scores on the BSI somatization and depression
subscales, BDI, and Piper Fatigue Scales for the
same period to determine whether the changes in
HRQOL measured by the FACT-BRM were
associated with changes in symptom burden,
depression, and fatigue. Results are presented in
Table 4. Significant correlations were seen between
changes in the FACT-BRM physical scale and the
somatization and depression scales of the BSI (all
p<0.005), and the behavioral, sensory, and cog-
nitive/affective scales of the RPFS (all p<0.01). In
each case, decreased physical QOL was associated
with increased complaints on the other scales.
Similar findings were observed for the FACT-
BRM emotional, functional, and additional con-
cerns scales with the BDI and BSI depression and
somatization scales.
Internal consistency
Coefficient a,s for each subscale of the FACT-
BRM were calculated at baseline and after
1 month of post-high dose administration. Base-
line a,s ranged from poor to excellent: functional
well-being 0.91, physical well-being 0.85,
emotional well-being 0.81, additional concerns –
mental 0.75, social/family well-being 0.50,
additional concerns – physical 0.30. Thus, the
internal consistency of the physical, functional,
and emotional well-being subscales is excellent,
and while it is adequate for the additional concerns
– cognitive/emotional subscale, it is considerably
lower for the social/family well-being and
additional concerns – physical scales. a,s at the
post-high dose administration assessment point
are higher, reflecting improved reliability in mea-
suring QOL once patients are on IFN: functional
well-being 0.91, emotional well-being 0.83, social/
family well-being 0.82, additional concerns – cog-
nitive/emotional 0.79, physical well-being 0.73,
and additional concerns – physical 0.61.
Test–retest reliability
To evaluate the stability of the FACT-BRM, 1-
month test–retest reliability correlations were
conducted on subscale scores from the mainte-
nance phase of IFN administration. Scores from
after 1 and 2 months of maintenance therapy were
compared. Reliability for the functional subscale
was in the excellent range (r ¼ 0.89, p < 0.001), in
the good range for the physical (r ¼ 0.79,
p < 0.005) and emotional subscales (r ¼ 0.77,
Table 4. Sensitivity to change: change score correlations baseline to post-high dose (n = 21)
FACT-BRM FACT





BSI somatization )0.730** )0.553** )0.734* )0.582** )0.572** )0.817***
p = 0.001 p = 0.021 p = 0.001 p = 0.014 p = 0.016 0.000
BSI depression )0.669* )0.489** )0.769* )0.460 )0.478 )0.779***
p = 0.003 p = 0.046 p<0.000 p = 0.063 p = 0.052 0.000
Beck depression inventory )0.492** )0.661* )0.741* )0.196 )0.532** )0.648*
p = 0.045 p = 0.004 p = 0.001 p = 0.451 p = 0.028 0.005
Piper fatigue behavioral )0.634* )0.442 )0.464 )0.397 )0.490** )0.600**
p = 0.006 p = 0.076 p = 0.061 p = 0.114 p = 0.046 0.011
Piper fatigue affective )0.274 )0.452 )0.310 )0.097 )0.416 )0.358
p = 0.286 p = 0.069 p = 0.225 p = 0.712 p = 0.097 0.159
Piper fatigue sensory )0.671* )0.346 )0.562** )0.433 )0.459 )0.636*
p = 0.003 p = 0.174 p = 0.019 p = 0.082 p = 0.064 0.006
Piper fatigue cognitive )0.617* )0.500** )0.801* )0.245 )0.450 )0.684*
p = 0.008 p = 0.041 p < 0.000 p = 0.342 p = 0.070 0.002
*p<0.001; **p<0.05.
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p<0.01), and in the acceptable range for the
additional concerns – mental (r ¼ 0.68, p<0.05)
and social/family subscales (r ¼ 0.68, p<0.05).
Reliability for the additional concerns – physical
subscale was not statistically significant (r ¼ 0.51,
p>0.05). These results are consistent with the re-
ported health of the melanoma patients, which did
not change significantly during the first and second
months of maintenance therapy [21]. Thus, all
correlations were significant, with the exception of
the additional concerns – physical subscale, which
demonstrated a trend in the same direction and
approached statistical significance.
Discussion
The current paper reports the results of validity
and reliability analyses of a new, specific measure
of QOL, the FACT-BRM, as part of a larger study
measuring levels of depression, distress, and fati-
gue prospectively over the full 12 month course of
therapy among patients taking high-dose inter-
feron for melanoma.
The FACT-BRM demonstrated good concur-
rent validity when compared with the BDI, and
subscales of the BSI and RPFS. All correlations
were in expected directions, demonstrating good
convergent and discriminant validity. FACT-
BRM subscales correlated with measures of fati-
gue, symptom burden, and depression, as
hypothesized. Although unexpected correlations
were also found with measures of anxiety (as
measured by the anxiety and obsessive–compulsive
subcales of the BSI), they were highly significant
and consistent across subscales of the FACT-
BRM, making it unlikely that they are the result of
chance. Also, since these correlations were from
scores at the post-high dose point, participants had
already been on IFN for 1 month, making antici-
patory anxiety an unlikely explanation. It is pos-
sible that these correlations indicate health-related
concerns and anxiety among the patients receiving
interferon, which has not been a focus of previous
research. It is also possible that the correlations
between HRQOL dimensions and measures of
anxiety reflect the occurrence of arousal symptoms
(e.g., feeling shaky) precipitated by interferon, ra-
ther than anxiety. Alternatively, it may indicate
the presence of other effects of high dose IFN
therapy, heretofore unidentified in the literature.
The results are too consistent to simply dismiss,
and we would suggest that future research may
elucidate this possibility further.
The FACT-BRM also demonstrated excellent
sensitivity to change by measuring significant dif-
ferences in mean scores on almost all subscales of
the FACT from pre-administration baseline to
post-high dose IFN administration. The validity of
the changes noted is supported by consistent cor-
relations with changes on other measures over the
same time period.
With regard to reliability, coefficient a,s indi-
cated adequate internal consistency at the baseline
administration point, before participants were on
IFN. These improved substantially after one
month of high-dose therapy, indicating good
internal consistency in measuring HRQOL among
participants receiving high-dose IFN. One month
test–retest correlations also indicated adequate
stability over time.
The current study utilized data from a small, but
significant group of melanoma patients who are at
risk for recurrence and have few treatment alter-
natives. In general, scores indicated increased
symptoms of depression, symptom burden, and
fatigue following IFN administration, which is
consistent with findings reported in the growing
literature on BRMs generally. As expected, these
results correlated significantly with decreased
HRQOL across a number of dimensions. Results
document the FACT-BRM’s ability to track
changes in symptoms and QOL experienced over
time by patients receiving high-dose IFN. Thus,
the FACT-BRM appears to be a sensitive, valid,
and reliable measure of HRQOL among patients
receiving high-dose IFN-a-2b.
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